Compare SSYS & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSYS | ANNX |
|---|---|---|
| Founded | 1989 | 2011 |
| Country | United States | United States |
| Employees | 1779 | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 944.9M | 918.2M |
| IPO Year | 1994 | 2020 |
| Metric | SSYS | ANNX |
|---|---|---|
| Price | $11.05 | $6.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $12.75 | ★ $16.50 |
| AVG Volume (30 Days) | 1.2M | ★ 2.5M |
| Earning Date | 03-04-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $561,461,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.76 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.12 | $1.29 |
| 52 Week High | $12.88 | $7.18 |
| Indicator | SSYS | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 60.40 | 69.15 |
| Support Level | $10.74 | $5.85 |
| Resistance Level | $11.69 | $6.83 |
| Average True Range (ATR) | 0.63 | 0.48 |
| MACD | 0.12 | 0.10 |
| Stochastic Oscillator | 61.54 | 86.53 |
Stratasys Ltd is a polymer-based 3D printing solution, which provides a product life cycle, with multiple technologies and complete solutions for superior application fit, across industrial, healthcare, and consumer fields. It focuses, in particular, on polymer 3D printing solutions that address the fastest-growing manufacturing solutions viewed as the potential growth opportunity in the 3D printing industry. Its printers include FDM, PolyJet, Stereolithography, P3, and SAF. Its software is GrabCAD Software, Connectivity, Digital Anatomy Creator, and OpenAM Software. It generates revenue through 3D printing systems, related services, and consumables and by providing additive manufacturing solutions.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.